Allergan’s Viberzi (eluxadoline) now available in the US
15 December 2015 | By Victoria White
Viberzi, a twice daily, oral medication, is Allergan’s first-in-class treatment for irritable bowel syndrome with diarrhoea (IBS-D)...
List view / Grid view
News
Amgen reacquires product rights to 3 products from GSK
15 December 2015 | By Victoria White
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries...
Sanofi and Boehringer Ingelheim announce business swap
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
Trial of Ofev and pirfenidone in IPF starts
14 December 2015 | By Victoria White
The trial’s primary endpoint is the percentage of patients with on-treatment gastrointestinal adverse events from baseline to week 12...
FDA approves Vistogard to treat 5-FU or capecitabine overdoses
14 December 2015 | By Victoria White
Vistogard is the first and only antidote for 5-FU and capecitabine overdose and for earlyonset, severe, life-threatening toxicities approved by the FDA...
Nurofen Australia made misleading Specific Pain claims
14 December 2015 | By Victoria White
The Australian Federal Court has found that Reckitt Bensicker (Australia) engaged in misleading conduct in contravention of Australia Consumer Law by representing that its Nurofen Specific Pain Products were each formulated to treat a specific type of pain...
AstraZeneca confirms talks with Acerta Pharma to acquire the company for $5 billion
AstraZeneca today confirmed that it is in talks with Acerta Pharma to acquire the company in a potential deal worth $5 billion.
Cherwell strengthens team with Microbiology Product Specialist appointment
14 December 2015 | By Cherwell Laboratories
Company boosts industrial microbiology expertise to enhance customer support...
Takeda’s Ninlaro capsules now available in the US
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
FDA approves Roche’s Alecensa for ALK-positive NSCLC
14 December 2015 | By Victoria White
Alecensa (alectinib) is approved for patients whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib)...
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
NICE says ‘yes’ to heart failure drug sacubitril valsartan
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
NICE changes decision on AstraZeneca’s olaparib
11 December 2015 | By Victoria White
NICE intends to recommend Lynparza (olaparib) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer after AstraZeneca provided more information on the drug...
New data for Eisai’s eribulin presented at SABCS
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
NICE recommends enzalutamide; consults on abiraterone
11 December 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has published draft guidance on two prostate cancer treatments - enzalutamide and abiraterone...
